Clinical Trials Logo

Clinical Trial Summary

The primary objective of the study is to describe the safety and tolerability of fasinumab, including adverse events of special interest (AESIs), in patients with pain due to radiographically-confirmed OA of the knee or hip.


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT02683239
Study type Interventional
Source Regeneron Pharmaceuticals
Contact
Status Completed
Phase Phase 3
Start date February 17, 2016
Completion date June 15, 2021

See also
  Status Clinical Trial Phase
Recruiting NCT06230081 - Comparison Between Blocks or Not in Joint Arthroplasty N/A